H. Tatum

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

Gregory T. Everson, Karen Sims, M. Rodríguez‐Torres et al. · Gastroenterology · 2013 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

Stanislas Pol, Reem Ghalib, Vinod K. Rustgi et al. · The Lancet Infectious Diseases · 2012 · 147 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 135 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Christophe Hézode, Gideon M. Hirschfield, Wayne Ghesquière et al. · Gut · 2014 · 119 citations

Medicine, Pharmacology, Pharmacotherapy +15

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid

Stephen R. Lee, Keith Kardos, Eugene R. Schiff et al. · Journal of Virological Methods · 2010 · 113 citations

Veterinary Medicine, Infectious Diseases, Microbiology +15